By J.J. McGrath
Combatants on the front lines in the war on cancer have a new weapon in the arsenal, as the U.S. Food and Drug Administration on Friday OK'd Perjeta -- flanked by Herceptin and docetaxel -- for deployment in a three-pronged attack on the enemy cells in people with HER2-positive metastatic breast cancer.
Recipient's E-mail |
(Separate multiple e-mail addresses with commas. Limited to 20 addresses. Your recipients' e-mail addresses will be saved for your convenience. The e-mail addresses that you supply to use this service will not be shared with any third parties.) |
Your E-mail |
|